OS at the time of first POD (OS-2). (A) OS-2 in all 25 patients with relapsed/refractory disease, (B) OS-2 in patients who received ibrutinib as second line (n = 6) vs other patients with relapsed and treated patients (n = 16), and (C) POD-24 in 25 patients who had relapsed/refractory disease: early- vs late-POD.